Author: admin
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical gel 10% for treating mild-to-moderate actinic keratoses (AKs). The randomised, double-blind trial is comparing Ameluz with a vehicle gel in treating AK on the extremities, neck and trunk, using the RhodoLED lamp photodynamic therapy (PDT). It has been designed to evaluate Ameluz’s efficacy and safety as a PDT after the application of one to three tubes of the product on surface areas of nearly 80cm², 160cm² or 240cm². Subjects who still have at least one lesion after receiving either Ameluz…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from the cybersecurity startup’s pending sale to Google parent Alphabet Inc., according to a person with knowledge of the matter. Most Read from Bloomberg The multiple on invested capital, known as MOIC, is calculated based on Sequoia’s roughly 10% stake in Wiz, which Alphabet agreed to buy for $32 billion in cash. Sequoia is set to reap about $3 billion from the sale, said the person, who asked not to be identified discussing private information. Sequoia is one of several venture…